BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.…
BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
BioNexus Gene Lab (NASDAQ: BGLC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 19 employees.
The shares were at 0.6800 USD on 20 November 2026, down 86.8% over 52 weeks. Its 52-week range is 0.6586 USD to 5.130 USD: the price is 86.7% below the high and 3.2% above the low.
Its market capitalisation is 1.99M USD.
BioNexus Gene Lab reports return on equity of -34.6%, an operating margin of -88.2% and revenue down 96.6% year over year.
It holds more cash than debt, a net cash position of 3.20M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.